Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

News | Renal Denervation

Renal Denervation Effective in Patients With Untreated Hypertension

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

April 01, 2020

News | Renal Denervation

Renal Denervation Effective in Patients With Untreated Hypertension

April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...

April 01, 2020

Videos | Structural Heart

VIDEO: TAVR Performs as Well as Surgery in Low-Risk Patients

A review of the PARTNER 3 Low-Risk Trial with Michael Mack, M.D., chairman, cardiovascular service line, Baylor Scott ...

April 01, 2020

William O’Neill, M.D., Henry Ford Hospital, speaking at the announcement of the creation of the Cardiogenic Shock Initiative in 2016. O'Neill asked the same partner hospitals in the Detroit area to pool resources to create a COVID-19 study group to help speed the gathering of data in COVID-19 drug trials.

News | Coronavirus (COVID-19)

Cardiologists Head COVID-19 Trial Collaboration in Detroit Area Hospitals

March 31, 2020 — Four metropolitan Detroit hospital systems and a leading research university announced a collaboration ...

March 31, 2020

News

E-Cigarettes More Effective Than Counseling for Smoking Cessation

March 30, 2020 — Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes) ...

March 30, 2020

Closing access to the radial artery after harvesting a section of the artery for a coronary artery bypass graft (CABG). Photo by Getty Images. #ACC20 #ACC2020

News | Cardiovascular Surgery

Radial Artery Versus Saphenous Vein For Coronary Bypass Surgery Long Term Follow-up

March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when ...

March 30, 2020

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

News | Heart Valve Technology

Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials in Response to Hospitals' COVID-19 Focus

March 30, 2020 — Edwards Lifesciences Corp. announced it is temporarily pausing new enrollments in its active pivotal ...

March 30, 2020

Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

News | Heart Valve Technology

TAVR Non-Inferior to Surgery in U.K. Review of Surgery vs. TAVR

March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did ...

March 30, 2020

PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR

Feature | Heart Valve Technology

TAVR Equivalent to Surgery at Two Years in Low-Risk Patients

March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well ...

March 30, 2020

News | Heart Valve Technology

U.S. TAVR Outcomes Need Improvement Based on TVT Registry Analysis

March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing ...

March 29, 2020

$Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio$

News | Heart Failure

Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

March 29, 2020

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020

Feature | Heart Valve Technology | Dave Fornell, Editor

TAVR Shows Favorable Safety in Patients with Bicuspid Valve

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve ...

March 29, 2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

News | Pharmaceuticals | Dave Fornell, Editor

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

March 28, 2020

Find more news from ACC 2020.Women carry heavier burden of chest pain, but less artery narrowing according to data in a substudy of the ISCHEMIA Trial. #ACC20 #ACC2020 #ISCHEMIA

News | Womens Cardiovascular Health

Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial

March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia) ...

March 28, 2020

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020